Bisphosphonate therapy for fibrous dysplasia

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Bony fibrous dysplasia is one of the hallmark features of McCune-Albright syndrome. Fibrous dysplasia can result in pain, fracture and deformity in affected areas. A number of observational, uncontrolled reports have been published outlining results of bisphosphonate therapy for fibrous dysplasia. Bisphosphonates are well tolerated and appear to be useful for reducing bone pain. Although their use is also associated with decreases in bone turnover, increases in bone density and radiological changes, their impact on the overall course of the disease, particularly the incidence of fractures and deformity, is less clear. Many questions remain about optimizing their use for fibrous dysplasia therapy.

Original languageEnglish
Pages (from-to)440-445
Number of pages6
JournalPediatric Endocrinology Reviews
Volume4
Issue numberSUPPL. 4
StatePublished - Aug 2007

Fingerprint

Diphosphonates
Polyostotic Fibrous Dysplasia
Pain
Bone Remodeling
Bone Density
Bone and Bones
Incidence
Therapeutics

Keywords

  • Alendronate
  • Diphosphonates
  • Pain
  • Pamidronate alkaline phosphatase
  • Review
  • Zolendronic acid

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Bisphosphonate therapy for fibrous dysplasia. / DiMeglio, Linda.

In: Pediatric Endocrinology Reviews, Vol. 4, No. SUPPL. 4, 08.2007, p. 440-445.

Research output: Contribution to journalArticle

@article{b4d28f073de64cccae5864c08ebbe116,
title = "Bisphosphonate therapy for fibrous dysplasia",
abstract = "Bony fibrous dysplasia is one of the hallmark features of McCune-Albright syndrome. Fibrous dysplasia can result in pain, fracture and deformity in affected areas. A number of observational, uncontrolled reports have been published outlining results of bisphosphonate therapy for fibrous dysplasia. Bisphosphonates are well tolerated and appear to be useful for reducing bone pain. Although their use is also associated with decreases in bone turnover, increases in bone density and radiological changes, their impact on the overall course of the disease, particularly the incidence of fractures and deformity, is less clear. Many questions remain about optimizing their use for fibrous dysplasia therapy.",
keywords = "Alendronate, Diphosphonates, Pain, Pamidronate alkaline phosphatase, Review, Zolendronic acid",
author = "Linda DiMeglio",
year = "2007",
month = "8",
language = "English",
volume = "4",
pages = "440--445",
journal = "Pediatric Endocrinology Reviews",
issn = "1565-4753",
publisher = "YS Medical Media Ltd.",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Bisphosphonate therapy for fibrous dysplasia

AU - DiMeglio, Linda

PY - 2007/8

Y1 - 2007/8

N2 - Bony fibrous dysplasia is one of the hallmark features of McCune-Albright syndrome. Fibrous dysplasia can result in pain, fracture and deformity in affected areas. A number of observational, uncontrolled reports have been published outlining results of bisphosphonate therapy for fibrous dysplasia. Bisphosphonates are well tolerated and appear to be useful for reducing bone pain. Although their use is also associated with decreases in bone turnover, increases in bone density and radiological changes, their impact on the overall course of the disease, particularly the incidence of fractures and deformity, is less clear. Many questions remain about optimizing their use for fibrous dysplasia therapy.

AB - Bony fibrous dysplasia is one of the hallmark features of McCune-Albright syndrome. Fibrous dysplasia can result in pain, fracture and deformity in affected areas. A number of observational, uncontrolled reports have been published outlining results of bisphosphonate therapy for fibrous dysplasia. Bisphosphonates are well tolerated and appear to be useful for reducing bone pain. Although their use is also associated with decreases in bone turnover, increases in bone density and radiological changes, their impact on the overall course of the disease, particularly the incidence of fractures and deformity, is less clear. Many questions remain about optimizing their use for fibrous dysplasia therapy.

KW - Alendronate

KW - Diphosphonates

KW - Pain

KW - Pamidronate alkaline phosphatase

KW - Review

KW - Zolendronic acid

UR - http://www.scopus.com/inward/record.url?scp=35148876609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35148876609&partnerID=8YFLogxK

M3 - Article

C2 - 17982393

AN - SCOPUS:35148876609

VL - 4

SP - 440

EP - 445

JO - Pediatric Endocrinology Reviews

JF - Pediatric Endocrinology Reviews

SN - 1565-4753

IS - SUPPL. 4

ER -